Generalizability of Tau and Amyloid Plasma Biomarkers in Alzheimer's Disease Cohorts of Diverse Genetic Ancestries

- 3
- 4 Anthony J. Griswold^{1,2*}, Farid Rajabli^{1,2}, Tianjie Gu¹, Jamie Arvizu¹, Charles G. Golightly¹, Patrice L.
- 5 Whitehead¹, Kara L. Hamilton-Nelson¹, Larry D. Adams¹, Jose Javier Sanchez¹, Pedro R. Mena¹, Takiyah
- 6 D. Starks³, Maryenela Illanes-Manrique⁴, Concepcion Silva⁵, William S. Bush^{6,7}, Michael L. Cuccaro^{1,2},
- 7 Jeffery M. Vance^{1,2}, Mario R Cornejo-Olivas⁴, Briseida E. Feliciano-Astacio⁵, Goldie S. Byrd³, Gary W.
- 8 Beecham^{1,2}, Jonathan L. Haines^{6,7}, and Margaret A. Pericak-Vance^{1,2}
- 9
- 10 1) John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, 33136, USA;
- 2) Dr. John T Macdonald Foundation Department of Human Genetics, University of Miami, Miami, FL,
 33136, USA;
- 13 3) Maya Angelou Center for Health Equity, Wake Forest University, Winston-Salem, NC, 27102, USA;
- 4) Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, 15003, Peru;
- 15 5) Department of Internal Medicine, Universidad Central Del Caribe, Bayamón, Puerto Rico, 00960, USA;
- 16 6) Department of Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland,
- 17 OH, 44106, USA;
- 18 7) Cleveland Institute for Computational Biology, Cleveland, OH, 44106, USA;
- 19
- 20
- 21 *Corresponding Author:
- 22 Anthony J. Griswold, Ph.D.
- 23 Associate Professor of Human Genetics
- 24 The Dr. John T. Macdonald Foundation Department of Human Genetics
- 25 John P. Hussman Institute for Human Genomics
- 26 University of Miami Miller School of Medicine
- 27 1501 NW 10th Avenue (M-860), BRB 318
- 28 Miami, FL 33136
- 29 (305) 243-5982 (office)
- 30

31 Abstract

- 32
- **33** Introduction. Plasma phosphorylated threonine-181 of Tau and amyloid beta are biomarkers for
- 34 differential diagnosis and preclinical detection of Alzheimer disease (AD). Given differences in AD risk
- 35 across diverse populations, generalizability of existing biomarker data is not assured.
- 36 Methods. In 2,086 individuals of diverse genetic ancestries (African American, Caribbean Hispanic, and
- 37 Peruvians) we measured plasma pTau-181 and Aβ42/Aβ40. Differences in biomarkers between cohorts
- 38 and clinical diagnosis groups and the potential discriminative performance of the two biomarkers were
- 39 assessed.
- 40 **Results.** pTau-181 and Aβ42/Aβ40 were consistent across cohorts. Higher levels of pTau181 were
- 41 associated with AD while Aβ42/Aβ40 had minimal differences. Correspondingly, pTau-181 had greater
- 42 predictive value than $A\beta 42/A\beta 40$, however, the area under the curve differed between cohorts.
- 43 Discussion. pTau-181 as a plasma biomarker for clinical AD is generalizable across genetic ancestries,
- 44 but predictive value may differ. Combining genomic and biomarker data from diverse individuals will
- 45 increase understanding of genetic risk and refine clinical diagnoses.

46 Background

47	Alzheimer disease (AD) is a progressive and devastating neurodegenerative condition with a
48	prevalence of 5% in individuals 65-74 years of age, increasing to 33% by 85 years of age. This
49	corresponds to 6.7 million people in the US with a current diagnosis of AD, which is estimated to
50	increase to 14 million by 2060.[1] AD has a global impact, with diverse populations around the world
51	affected, but ancestrally diverse groups such as African American (AA) and Hispanic (HI) populations
52	are underrepresented in AD genomic and translational studies[2-11] which in part contributes to health
53	disparities in the US. Compared to Non-Hispanic White (NHW) populations AA populations have higher
54	frequencies of risk factors for complex diseases such as AD, more limited access to health services,
55	poorer health outcomes, and lower life expectancies[12-17] For example, Caribbean HI are twice as likely
56	as non-Hispanic Whites (NHW) to have late-onset AD[18,19] and the incidence of new AD cases in
57	Caribbean HI families is three times the incidence in NHW families.[20] Similarly, compared with NHW
58	individuals, individuals of African ancestry, even from the same local community, are twice as likely to
59	develop AD due to both genetic and environmental influences.[19]
60	In part, these disparities can be attributed to access to and affordability of AD diagnostic tools
61	such as magnetic resonance imaging (MRI), positron emission tomography (PET) imaging, and
62	cerebrospinal fluid (CSF) assays that can be incorporated as criteria for pre-clinical AD diagnosis.[21]
63	Therefore, the use of AD plasma biomarkers have begun wide use to assist in clinical diagnosis and refine
64	the preclinical stages of AD and MCI.[22-24] These blood-based biomarkers can be used to estimate the
65	underlying biological changes associated with AD diagnosis and prognosis including amyloid deposition
66	(plasma A β 42/A β 40 ratio)[25] and tau hyperphosphorylation and tangles (phosphorylated Tau).[26,27]
67	Critically, however, individuals of African and HI ancestry are underrepresented in most research
68	studies[7-9] including genomic and translational studies,[11,28,29] and particularly for those utilizing AD
69	plasma biomarkers.[30,31] Thus, diverse ancestral groups may not benefit to the same degree as NHW
70	from the clinical applications of genomic and biomarker studies [32-37]. While recent studies have

increased representation of African Americans[30,38] and Hispanics,[39,40] the sample sizes of diverse
individuals remain a small proportion of the total study cohorts making conclusive statements on the
generalizability of these findings difficult.

To address the issues of lack of representation of diverse ancestries in AD biomarker studies. 74 75 potential differences in AD biomarkers across populations, and the generalizability of AD biomarkers to 76 discriminate between clinically diagnosed AD and cognitively unimpaired (CU) individuals, herein we 77 measured plasma AD related biomarkers pTau-181 and Aβ42/Aβ40 ratio in a large cohort of individuals 78 representing diverse ancestral backgrounds. In these clinically diagnosed cohorts, we compare biomarker concentration between those diagnosed with AD, mild cognitive impairment (MCI), CU across and within 79 80 the groups. Furthermore, we explore the ability of these biomarkers to discriminate between AD and CU 81 in these diverse sets of individuals. As such, we can better understand the generalizability and utility of these lower-cost and readily available biomarkers for broad use in AD diagnostics in individuals of 82 83 diverse genetic ancestry.

84

85 Methods

86 Ascertainment of Study Participants

87 Individuals for this study have been ascertained through multiple studies of AD genetics across 88 several sites focused on individuals from underrepresented populations including self-identified Black 89 Americans of African ancestry and Hispanics (Puerto Ricans, Cuban Americans, and Peruvians). The study sites include: the University of Miami (Miami, FL, USA), Wake Forest University (Winston-Salem, 90 91 NC, USA), Case Western Reserve University (Cleveland, OH, USA), Universidad Central del Caribe 92 (Bayamon, PR, USA), and Instituto Nacional de Ciencias Neurologicas (Lima, Peru). All participants or 93 their proxy provided written informed consent as part of the study protocols approved by the site-specific 94 Institutional Review Boards.

95 Ascertainment protocols were consistent across sites and clinical data assessments capture
96 sociodemographic information, medical and family history, dementia staging, AD/dementia symptoms,

97 neuropsychological abilities, functional capabilities, and behavioral impairments. Best-estimate diagnoses
98 were generated by a consensus committee consisting of a board-certified neurologist, a physician
99 specializing in dementia, and clinical neuropsychologists, all with expertise in adjudication of
100 AD/dementia. Using all available clinical information, participants were assigned best-estimate clinical
101 diagnoses (AD, MCI, or CU) based on criteria adapted from NIA-Alzheimer's Association
102 criteria.[21,41,42]

103 *Genotyping and Assessment of Genetic Ancestry*

2,086 total participants were included in this study and classified based on their self-reported 104 105 race-ethnicity and country of origin as African American (AA), Caribbean Hispanic (Puerto Rican or 106 Cuban American), or Peruvian (PE). For each participant, whole genome genotyping array data on the 107 Illumina Global Screening Array (Illumina, San Diego, CA, USA) was generated. Genotype markers were quality controlled to include only those with high call rate (over 97%) and minor allele frequency 108 109 over 0.05 within each population. Genetic relatedness was evaluated using the GENESIS R package.[43] Frist, the KING-Robust kinship coefficient estimator was used to calculate the KING matrix that includes 110 111 pairwise relatedness and measures of pairwise ancestry divergence.[44] The PC-AiR method used 112 ancestry divergence from KING-Robust estimate to perform PCA, which then was used by PC-Relate to estimate pairwise kinship coefficients. Genetically related individuals with closer than 4th-degree relatives 113 were identified and only one sample per related group was retained in the analysis. Subsequently, PC-Air 114 was applied to calculate global ancestry using four reference populations were used including AI, EU, 115 AF, and EA from Human Genome Diversity Project (HGDP) data for the reference populations.[45] 116 117 Admixture proportions were estimated using a model-based clustering algorithm was performed as implemented in the ADMIXTURE software[46] with K=4 for the reference populations. 118 119 Measurement of Plasma AD Biomarkers

Whole blood tubes were collected from the 2,086 participants at the time of study entry by trainedphlebotomists. Plasma was isolated from EDTA tubes via centrifugation, aliquoted into polypropylene

122	tubes, and stored at -80°C until further analysis. For a set of African American participants, coagulation
123	was performed in the tube and thus serum was the only available blood fluid available. Plasma/serum
124	concentrations of pTau-181, A β 42, and A β 40 were measured using SIMOA chemistry implemented on
125	the Quanterix HD-X analyzer (Quanterix, Billerica, MA, USA)[47] according to manufacturer's
126	instructions for the pTau-181 Advantage V2 assay and Neurology 3-Plex A assay. Samples were
127	randomized according to age (at time of blood collection), sex, and diagnosis and assayed in duplicate on
128	each Simoa plate. Initial data analysis was performed using the Quanterix Analyzer v1.6 software to
129	calculate standard curves and biomarker concentrations. After quality control including removing of
130	related participants, failed biomarker assays, and removal of outliers greater than three standard
131	deviations from the mean 1,368 participants with plasma and 721 participants with serum remained in the
132	analyses (Table 1).

134 Table 1. Characteristics of the study participants and biomarker levels

Plasma Samples

		African	Caribbean	
Alzheimer's Disease	All samples	American	Hispanic	Peruvian
	(N=421)	(N=71)	(N=312)	(N=38)
Sex				
Female	283 (67.2%)	47 (66.2%)	209 (67.0%)	27 (71.1%)
Male	138 (32.8%)	24 (33.8%)	103 (33.0%)	11 (28.9%)
Age (years)				
Mean (SD)	79.4 (7.85)	80.0 (8.48)	79.3 (7.76)	79.8 (7.59)
pTau181 level (pg/mL)				
Mean (SD)	2.76 (1.81)	3.00 (1.49)	2.68 (1.87)	3.08 (1.81)
Αβ42/40				
Mean (SD)	0.0410 (0.0137)	0.0478 (0.0159)	0.0402 (0.0130)	0.0352 (0.00990)
Mildly Cognitive		African	Caribbean	
Impaired	All samples	American	Hispanic	Peruvian
Impuneu	(N=270)	(N=88)	(N=182)	(N=0)
Sex				-
Female	193 (71.5%)	67 (76.1%)	126 (69.2%)	-
Male	77 (28.5%)	21 (23.9%)	56 (30.8%)	-
Age (years)				-
Mean (SD)	74.9 (7.36)	72.7 (7.36)	75.9 (7.15)	-
pTau181 level (pg/mL)				-
Mean (SD)	1.91 (1.26)	1.90 (1.46)	1.92 (1.15)	-
Αβ42/40				-
Mean (SD)	0.0455 (0.0149)	0.0536 (0.0168)	0.0418 (0.0123)	-
C		African	Caribbean	
Unimpaired	All samples	American	Hispanic	Peruvian
	(N=677)	(N=234)	(N=355)	(N=88)
Sex				
Female	533 (78.7%)	197 (84.2%)	270 (76.1%)	66 (75.0%)
Male	144 (21.3%)	37 (15.8%)	85 (23.9%)	22 (25.0%)
Age (years)				
Mean (SD)	73.2 (7.23)	70.9 (6.73)	74.7 (7.36)	72.9 (6.41)
pTau181 level (pg/mL)				
Mean (SD)	1.98 (2.60)	2.02 (4.15)	1.84 (1.05)	2.40 (1.22)
Αβ42/40				
Mean (SD)	0.0477 (0.0247)	0.0575 (0.0196)	0.0432 (0.0275)	0.0408 (0.0138)

135

136

	CU	MCI	AD	Overall
	(N=370)	(N=103)	(N=248)	(N=721)
Sex				
Female	275 (74.3%)	81 (78.6%)	194 (78.2%)	550 (76.3%)
Male	95 (25.7%)	22 (21.4%)	54 (21.8%)	171 (23.7%)
Age (years)				
Mean (SD)	69.5 (6.74)	73.6 (7.03)	80.8 (8.12)	74.0 (8.89)
pTau181 level (pg/mL)				
Mean (SD)	1.50 (1.46)	1.18 (1.22)	2.69 (2.26)	1.86 (1.85)
Αβ42/40				
Mean (SD)	0.0542 (0.113)	0.0481 (0.0182)	0.0491 (0.0458)	0.0519 (0.0899)

African American Serum Samples

138

139 Biomarker Statistical Analysis

140 Biomarker concentrations were log10-transformed to satisfy normality assumptions in the

141 downstream analysis. The differences in biomarker levels across ancestral groups and between AD, MCI

and CU individuals was analyzed using a linear regression model adjusted for age, sex, and population

substructure (principal components 1-3) followed by the post hoc least significant difference test for

144 pairwise group comparison and adjusted for multiple comparisons by Bonferroni.

145 To assess the diagnostic performance and construct receiver operator characteristic (ROC) curves,

146 we employed three logistic regression models: pTau-181 concentration alone, $A\beta 42/A\beta 40$ alone, and

147 pTau-181 concentration and $A\beta 42/A\beta 40$ together. For this analysis we used only individuals having data

available on both pTau-181 and A β 42/A β 40 biomarkers (N = 1,298 for plasma, N = 260 for serum). Area

149 under the curves (AUC) of the three models were compared using the DeLong test and adjusted for

150 multiple comparisons (Bonferroni). All analysis were performed using R v.4.1.1 with packages:

151 ImerTest,[48] multcomp,[49] Ismeans,[50] and pROC,[51] and visualizations created with ggpubr.[52]

152 **Results**

153 Global Genetic Ancestry of Participants

154 As detailed in Table 1, the participants in this study were ascertained as part of four distinct

155 cohorts: African American (AA), and HI with origins from the Caribbean (CH - Puerto Rican or Cuban

156 American) or Peru (PE). Figure 1A illustrates principal component analysis results of the study samples 157 and four continental populations from the HGDP reference panel. Genomic admixture varied widely 158 across cohorts with respect to proportions of European, African, Amerindian, and East Asian ancestries 159 (Figure 1B). Given similarity of ancestral admixture between Puerto Ricans and Cuban Americans and 160 the relatively small sample size of Cuban Americans, these cohorts were combined in further analysis as 161 Caribbean Hispanics. Global ancestry analysis confirmed primarily two-way admixture in AA (African 162 and European), three-way admixture in CH (African, European, and Amerindian), and four-way 163 admixture in PE (African, European, Amerindian, and East Asian) with a high proportion of Amerindian 164 background. 165 *Plasma pTau-181 and AB42/AB40 ratios across ancestries* We first set out to determine how AD plasma biomarker levels of pTau-181 and $A\beta 42/A\beta 40$ 166 167 compare across ancestries, within each diagnostic category of AD or CU. In general, plasma pTau-181 168 concentrations were consistent across these populations. There was a modest but significant increase in Peruvian controls relative to the other two groups (p=0.02 vs. AA, p=0.002 vs. CH), Figure 2A), but 169 among AD there were no significant differences between groups (Figure 2B). The $A\beta 42/A\beta 40$ ratio was 170 significantly higher in African Americans relative to the other two groups in the CU comparison 171 $p=2.38 \times 10^{-7}$ vs Peurivan, $p=4.36 \times 10^{-7}$ vs CHI, Figure 2C) and also trending higher in AD with a 172 significant difference between AA and CH (p = 0.05, Figure 2D). 173

174 Plasma pTau-181 and $A\beta 42/A\beta 40$ comparisons

Plasma pTau-181 concentrations were significantly increased in individuals with diagnosed clinical AD compared to CU and MCI ($p = 1.67 \times 10^{-13}$, Figure 3A) considering all individuals across all cohorts (Figure 3A). When analyzing each cohort separately, plasma pTau-181 concentrations were significantly higher in AD vs CU in AA ($p = 1.88 \times 10^{-8}$, Figure 3B) and CH ($p = 3.13 \times 10^{-7}$, Figure 3D) with a trend that did not reach statistical significance for Peruvians (p = 0.07, Figure 3C). When considering AD vs MCI, there was again a statistically higher pTau-181 concentration in overall (p =7.83x10⁻⁸, Figure 3A) as well AA ($p = 7.95 \times 10^{-5}$, Figure 3B) and CH ($p = 5.25 \times 10^{-5}$, Figure 3D). The

- 182 plasma A β 42/A β 40 ratio was significantly lower in AD of AA relative to CU (p = 0.02, Figure 4A-D).
- 183 There was no statistically significant difference in the concentration of pTau-181 nor $A\beta 42/A\beta 40$ ratio
- 184 between MCI and CU when considering all data together or when looking at specific cohorts individually.
- 185 Serum pTau-181 and $A\beta 42/A\beta 40$ comparisons
- 186 We analyzed the biomarkers in a subset of African ancestry individuals for whom only serum,
- 187 rather than plasma, was available. We first evaluated potential differences between serum and plasma
- 188 pTau-181 and Aβ42/Aβ40 ratio within each diagnostic category for African Americans. Plasma pTau-181
- 189 concentration was higher than serum in both CU ($p = 9.16 \times 10^{-6}$, Figure 5A) and AD ($p = 1.63 \times 10^{-3}$,
- 190 Figure 5B). The A β 42/A β 40 ratio was lower in serum in both CU (p = 2.44x10⁻¹³, Figure 5C) and AD (p
- 191 = 0.05, Figure 5D). Given these differences, we performed analysis within these serum samples
- separately. Like the plasma analysis, serum pTau-181 concentrations were significantly increased in
- 193 individuals with diagnosed clinical AD compared to either CU or MCI (Figure 6A). Also, the serum
- 194 $A\beta 42/A\beta 40$ ratio did not significantly differ (Figure 6B).
- 195 Discriminatory analysis of plasma and serum pTau-181 and $A\beta 42/A\beta 40$
- 196 We used logistic regression models to assess the accuracy of plasma and serum pTau-181
- 197 concentration and $A\beta 42/A\beta 40$ ratio in predicting clinical disease status. We evaluated the performance of
- 198 each biomarker individually and then in combination using the area under the receiver operating
- 199 characteristic curve (AROC) for each model (Figure 7). In general, pTau-181 was better at predicting
- status than $A\beta 42/A\beta 40$ ratio, and the classification improved slightly when both biomarkers were used
- together. Notably, the accuracy varies over the individual cohorts with combined AROC ranging from
- 202 0.85 in plasma measurements for African Americans to 0.65 in Peruvians.
- 203 Discussion

Herein, we have performed the largest to date study of plasma biomarkers in diverse ancestral AD
 cohorts. Importantly, we found that the plasma concentrations of pTau-181 are generally consistent across
 populations within clinical diagnostic categories, with a small elevation in Peruvian CU relative to
 African Americans and Caribbean Hispanics, while the Aβ42/Aβ40 ratio was higher in African American

208 AD and CU cohorts relative to Peruvians or Caribbean Hispanics. Moreover, we found that the plasma/serum concentration of pTau-181 was significantly greater in AD relative to CU and MCI across 209 210 these diverse ancestral cohorts. We did not detect differences between the statuses when comparing the 211 A\beta42/A\beta40 ratio across or within the cohorts. These correspond to pTau-181 offering strong predictive 212 value of AD status in these data, with $A\beta 42/A\beta 40$ adding little more to the model. Interestingly, however, 213 the predictive values varied widely across the ancestral groups ranging from 0.85 (AA) to 0.65 (PE). 214 The pTau-181 results generally reflect work done in previous large cohort studies done primarily 215 in European non-Hispanic White (NHW) individuals showing it to be strongly associated with AD 216 status[27]. Here we demonstrate generalizability of the pTau-181 biomarker in large cohorts of clinically 217 diagnosed individuals without stratification by alternative biomarkers such as PET imaging as had 218 previously been described for NHW.[53] Conversely, the $A\beta 42/A\beta 40$ ratio did not offer strong 219 association with AD status despite several previous reports of this association. While we cannot dismiss 220 the possibility that this is due to either ancestral diversity or the clinical diagnosis used in this study, it has been previously shown that the SIMOA chemistry assays for these analytes may lack the sensitivity 221 222 required to detect such differences [54]. In biomarker studies of more diverse individuals, the utility of 223 pTau-181 has been shown in predicting AD status in Caribbean Hispanics[39] as well as African 224 Americans.[38,55] However, the larger sample sizes of diverse cohorts reported here, 3-5 times larger 225 than previous, indicate that this is a robust and reproducible observation; that pTau-181 can be 226 incorporated in more diverse populations as a potential aide in diagnostic prediction. However, it is clear that this biomarker lacks complete discrimination of status as there is significant overlap in individual 227 228 values between AD, MCI, and CU. This suggests that pTau-181 should be combined with other clinical 229 tests and existing risk factors in making diagnostic decisions or could be used as longitudinal measure of 230 rate of change in progression toward dementia. 231 While pTau-181 was significantly higher in AD than MCI or CU across the diverse cohorts

232 investigated, there was a range of discriminatory AOC values represented. Notably in the Peruvian

cohort, the overall AROC value was lower (0.64) than in the other cohorts. The underlying reason for this
cannot be determined, though given the higher overall pTau-181 levels in Peruvian CU is likely to affect
this analysis. Intriguingly, this may be related to admixture of genetic ancestries altering the utility of
biomarkers in these cohorts. Further investigation related to the complex interplay between genetics,
social and environmental determinants of health, and AD biomarkers will be critical to continue to assess
these questions.

Overall, we provide further evidence that AD plasma biomarkers, particularly pTau-181, 239 240 can be used to discriminate between AD and MCI or CU not only in NHW populations but in ancestrally diverse cohorts. We have added significantly to the ongoing research in this area 241 while greatly increasing the inclusivity of individuals that have traditionally made up only a very 242 243 small proportion of participants in biomarker studies. Further confirmation of these observations in diverse cohorts including either autopsy confirmed individuals or those with extensive 244 diagnostic imaging could provide further validation of the use of these biomarkers in clinical 245 based cohorts while assisting in establishing ancestry specific cut-points for diagnostic purposes. 246 Ultimately, adding in AD plasma biomarkers with genetic and environmental information in 247 these diverse populations will continue to reveal the general and ancestry specific risk profile of 248 AD aiding in development of precision treatment strategies. 249

250

251 References

- [1] 2023 Alzheimer's disease facts and figures. Alzheimer's & Dementia 2023;19:1598-1695.
- 253 [2] G. Sirugo, S.M. Williams, S.A. Tishkoff, The Missing Diversity in Human Genetic Studies. Cell
- **254** 2019;177:26-31.
- 255 [3] G.W. Beecham, B. Vardarajan, E. Blue, W. Bush, J. Jaworski, S. Barral, A. DeStefano, K. Hamilton-
- 256 Nelson, B. Kunkle, E.R. Martin, A. Naj, F. Rajabli, C. Reitz, T. Thornton, C. van Duijn, A. Goate, S.
- 257 Seshadri, L.A. Farrer, E. Boerwinkle, G. Schellenberg, J.L. Haines, E. Wijsman, R. Mayeux, M.A.
- 258 Pericak-Vance, Alzheimer's Disease Sequencing Project, Rare genetic variation implicated in non-
- Hispanic white families with Alzheimer disease. Neurol Genet 2018;4:e286.
- 260 [4] J.C. Bis, X. Jian, B.W. Kunkle, Y. Chen, K.L. Hamilton-Nelson, W.S. Bush, W.J. Salerno, D.
- 261 Lancour, Y. Ma, A.E. Renton, E. Marcora, J.J. Farrell, Y. Zhao, L. Qu, S. Ahmad, N. Amin, P. Amouyel,
- 262 G.W. Beecham, J.E. Below, D. Campion, C. Charbonnier, J. Chung, P.K. Crane, C. Cruchaga, L.A.
- 263 Cupples, J.F. Dartigues, S. Debette, J.F. Deleuze, L. Fulton, S.B. Gabriel, E. Genin, R.A. Gibbs, A.
- 264 Goate, B. Grenier-Boley, N. Gupta, J.L. Haines, A.S. Havulinna, S. Helisalmi, M. Hiltunen, D.P.
- 265 Howrigan, M.A. Ikram, J. Kaprio, J. Konrad, A. Kuzma, E.S. Lander, M. Lathrop, T. Lehtimaki, H. Lin,
- 266 K. Mattila, R. Mayeux, D.M. Muzny, W. Nasser, B. Neale, K. Nho, G. Nicolas, D. Patel, M.A. Pericak-
- 267 Vance, M. Perola, B.M. Psaty, O. Quenez, F. Rajabli, R. Redon, C. Reitz, A.M. Remes, V. Salomaa, C.
- 268 Sarnowski, H. Schmidt, M. Schmidt, R. Schmidt, H. Soininen, T.A. Thornton, G. Tosto, C. Tzourio, S.J.
- van der Lee, C.M. van Duijn, B. Vardarajan, W. Wang, E. Wijsman, R.K. Wilson, D. Witten, K.C.
- 270 Worley, X. Zhang, Alzheimer's Disease Sequencing Project, C. Bellenguez, J.C. Lambert, M.I. Kurki, A.
- 271 Palotie, M. Daly, E. Boerwinkle, K.L. Lunetta, A.L. Destefano, J. Dupuis, E.R. Martin, G.D.
- 272 Schellenberg, S. Seshadri, A.C. Naj, M. Fornage, L.A. Farrer, Whole exome sequencing study identifies
- 273 novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional
- regulation. Mol Psychiatry 2018.
- [5] B.N. Vardarajan, S. Barral, J. Jaworski, G.W. Beecham, E. Blue, G. Tosto, D. Reyes-Dumeyer, M.
- 276 Medrano, R. Lantigua, A. Naj, T. Thornton, A. DeStefano, E. Martin, L.S. Wang, L. Brown, W. Bush, C.
- van Duijn, A. Goate, L. Farrer, J.L. Haines, E. Boerwinkle, G. Schellenberg, E. Wijsman, M.A. Pericak-
- 278 Vance, R. Mayeux, Alzheimer's Disease Sequencing Project, L.S. Wang, Whole genome sequencing of
- 279 Caribbean Hispanic families with late-onset Alzheimer's disease. Ann Clin Transl Neurol 2018;5:406-
- **280** 417.
- [6] B.W. Kunkle, B. Grenier-Boley, R. Sims, J.C. Bis, V. Damotte, A.C. Naj, A. Boland, M. Vronskaya,
- 282 S.J. van der Lee, A. Amlie-Wolf, C. Bellenguez, A. Frizatti, V. Chouraki, E.R. Martin, K. Sleegers, N.
- 283 Badarinarayan, J. Jakobsdottir, K.L. Hamilton-Nelson, S. Moreno-Grau, R. Olaso, R. Raybould, Y. Chen,
- A.B. Kuzma, M. Hiltunen, T. Morgan, S. Ahmad, B.N. Vardarajan, J. Epelbaum, P. Hoffmann, M.
- 285 Boada, G.W. Beecham, J.G. Garnier, D. Harold, A.L. Fitzpatrick, O. Valladares, M.L. Moutet, A.
- 286 Gerrish, A.V. Smith, L. Qu, D. Bacq, N. Denning, X. Jian, Y. Zhao, M. Del Zompo, N.C. Fox, S.H. Choi,
- 287 I. Mateo, J.T. Hughes, H.H. Adams, J. Malamon, F. Sanchez-Garcia, Y. Patel, J.A. Brody, B.A.
- 288 Dombroski, M.C.D. Naranjo, M. Daniilidou, G. Eiriksdottir, S. Mukherjee, D. Wallon, J. Uphill, T.
- Aspelund, L.B. Cantwell, F. Garzia, D. Galimberti, E. Hofer, M. Butkiewicz, B. Fin, E. Scarpini, C.
- 290 Sarnowski, W.S. Bush, S. Meslage, J. Kornhuber, C.C. White, Y. Song, R.C. Barber, S. Engelborghs, S.
- 291 Sordon, D. Voijnovic, P.M. Adams, R. Vandenberghe, M. Mayhaus, L.A. Cupples, M.S. Albert, P.P. De
- 292 Deyn, W. Gu, J.J. Himali, D. Beekly, A. Squassina, A.M. Hartmann, A. Orellana, D. Blacker, E.
- 293 Rodriguez-Rodriguez, S. Lovestone, M.E. Garcia, R.S. Doody, C. Munoz-Fernadez, R. Sussams, H. Lin,
- 294 T.J. Fairchild, Y.A. Benito, C. Holmes, H. Karamujic-Comic, M.P. Frosch, H. Thonberg, W. Maier, G.

295 Roschupkin, B. Ghetti, V. Giedraitis, A. Kawalia, S. Li, R.M. Huebinger, L. Kilander, S. Moebus, I. Hernandez, M.I. Kamboh, R. Brundin, J. Turton, Q. Yang, M.J. Katz, L. Concari, J. Lord, A.S. Beiser, 296 297 C.D. Keene, S. Helisalmi, I. Kloszewska, W.A. Kukull, A.M. Koivisto, A. Lynch, L. Tarraga, E.B. 298 Larson, A. Haapasalo, B. Lawlor, T.H. Mosley, R.B. Lipton, V. Solfrizzi, M. Gill, W.T. Longstreth Jr, 299 T.J. Montine, V. Frisardi, M. Diez-Fairen, F. Rivadeneira, R.C. Petersen, V. Deramecourt, I. Alvarez, F. 300 Salani, A. Ciaramella, E. Boerwinkle, E.M. Reiman, N. Fievet, J.I. Rotter, J.S. Reisch, O. Hanon, C. Cupidi, A.G. Andre Uitterlinden, D.R. Royall, C. Dufouil, R.G. Maletta, I. de Rojas, M. Sano, A. Brice, 301 302 R. Cecchetti, P.S. George-Hyslop, K. Ritchie, M. Tsolaki, D.W. Tsuang, B. Dubois, D. Craig, C.K. Wu, 303 H. Soininen, D. Avramidou, R.L. Albin, L. Fratiglioni, A. Germanou, L.G. Apostolova, L. Keller, M. Koutroumani, S.E. Arnold, F. Panza, O. Gkatzima, S. Asthana, D. Hannequin, P. Whitehead, C.S. 304 Atwood, P. Caffarra, H. Hampel, I. Quintela, A. Carracedo, L. Lannfelt, D.C. Rubinsztein, L.L. Barnes, 305 306 F. Pasquier, L. Frolich, S. Barral, B. McGuinness, T.G. Beach, J.A. Johnston, J.T. Becker, P. Passmore, 307 E.H. Bigio, J.M. Schott, T.D. Bird, J.D. Warren, B.F. Boeve, M.K. Lupton, J.D. Bowen, P. Proitsi, A. 308 Boxer, J.F. Powell, J.R. Burke, J.S.K. Kauwe, J.M. Burns, M. Mancuso, J.D. Buxbaum, U. Bonuccelli, N.J. Cairns, A. McOuillin, C. Cao, G. Livingston, C.S. Carlson, N.J. Bass, C.M. Carlsson, J. Hardy, R.M. 309 Carney, J. Bras, M.M. Carrasquillo, R. Guerreiro, M. Allen, H.C. Chui, E. Fisher, C. Masullo, E.A. 310 311 Crocco, C. DeCarli, G. Bisceglio, M. Dick, L. Ma, R. Duara, N.R. Graff-Radford, D.A. Evans, A. Hodges, K.M. Faber, M. Scherer, K.B. Fallon, M. Riemenschneider, D.W. Fardo, R. Heun, M.R. Farlow, 312 H. Kolsch, S. Ferris, M. Leber, T.M. Foroud, I. Heuser, D.R. Galasko, I. Giegling, M. Gearing, M. Hull, 313 314 D.H. Geschwind, J.R. Gilbert, J. Morris, R.C. Green, K. Mayo, J.H. Growdon, T. Feulner, R.L. Hamilton, 315 L.E. Harrell, D. Drichel, L.S. Honig, T.D. Cushion, M.J. Huentelman, P. Hollingworth, C.M. Hulette, 316 B.T. Hyman, R. Marshall, G.P. Jarvik, A. Meggy, E. Abner, G.E. Menzies, L.W. Jin, G. Leonenko, L.M. 317 Real, G.R. Jun, C.T. Baldwin, D. Grozeva, A. Karydas, G. Russo, J.A. Kaye, R. Kim, F. Jessen, N.W. 318 Kowall, B. Vellas, J.H. Kramer, E. Vardy, F.M. LaFerla, K.H. Jockel, J.J. Lah, M. Dichgans, J.B. 319 Leverenz, D. Mann, A.I. Levey, S. Pickering-Brown, A.P. Lieberman, N. Klopp, K.L. Lunetta, H.E. 320 Wichmann, C.G. Lyketsos, K. Morgan, D.C. Marson, K. Brown, F. Martiniuk, C. Medway, D.C. Mash, 321 M.M. Nothen, E. Masliah, N.M. Hooper, W.C. McCormick, A. Daniele, S.M. McCurry, A. Bayer, A.N. 322 McDavid, J. Gallacher, A.C. McKee, H. van den Bussche, M. Mesulam, C. Bravne, B.L. Miller, S. Riedel-Heller, C.A. Miller, J.W. Miller, A. Al-Chalabi, J.C. Morris, C.E. Shaw, A.J. Myers, J. Wiltfang, 323 S. O'Bryant, J.M. Olichney, V. Alvarez, J.E. Parisi, A.B. Singleton, H.L. Paulson, J. Collinge, W.R. 324 325 Perry, S. Mead, E. Peskind, D.H. Cribbs, M. Rossor, A. Pierce, N.S. Ryan, W.W. Poon, B. Nacmias, H. Potter, S. Sorbi, J.F. Quinn, E. Sacchinelli, A. Raj, G. Spalletta, M. Raskind, C. Caltagirone, P. Bossu, 326 327 M.D. Orfei, B. Reisberg, R. Clarke, C. Reitz, A.D. Smith, J.M. Ringman, D. Warden, E.D. Roberson, G. Wilcock, E. Rogaeva, A.C. Bruni, H.J. Rosen, M. Gallo, R.N. Rosenberg, Y. Ben-Shlomo, M.A. Sager, P. 328 Mecocci, A.J. Saykin, P. Pastor, M.L. Cuccaro, J.M. Vance, J.A. Schneider, L.S. Schneider, S. Slifer, 329 330 W.W. Seeley, A.G. Smith, J.A. Sonnen, S. Spina, R.A. Stern, R.H. Swerdlow, M. Tang, R.E. Tanzi, J.Q. Trojanowski, J.C. Troncoso, V.M. Van Deerlin, L.J. Van Eldik, H.V. Vinters, J.P. Vonsattel, S. 331 332 Weintraub, K.A. Welsh-Bohmer, K.C. Wilhelmsen, J. Williamson, T.S. Wingo, R.L. Woltjer, C.B. Wright, C.E. Yu, L. Yu, Y. Saba, (Alzheimer Disease Genetics Consortium, (European Alzheimer's 333 Disease Initiative, Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium, 334 335 (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental 336 Risk for Alzheimer's Disease Consortium (GERAD/PERADES), A. Pilotto, M.J. Bullido, O. Peters, P.K. 337 Crane, D. Bennett, P. Bosco, E. Coto, V. Boccardi, P.L. De Jager, A. Lleo, N. Warner, O.L. Lopez, M. 338 Ingelsson, P. Deloukas, C. Cruchaga, C. Graff, R. Gwilliam, M. Fornage, A.M. Goate, P. Sanchez-Juan, P.G. Kehoe, N. Amin, N. Ertekin-Taner, C. Berr, S. Debette, S. Love, L.J. Launer, S.G. Younkin, J.F. 339 Dartigues, C. Corcoran, M.A. Ikram, D.W. Dickson, G. Nicolas, D. Campion, J. Tschanz, H. Schmidt, H. 340 341 Hakonarson, J. Clarimon, R. Munger, R. Schmidt, L.A. Farrer, C. Van Broeckhoven, M. C O'Donovan, A.L. DeStefano, L. Jones, J.L. Haines, J.F. Deleuze, M.J. Owen, V. Gudnason, R. Mayeux, V. Escott-342 343 Price, B.M. Psaty, A. Ramirez, L.S. Wang, A. Ruiz, C.M. van Duijn, P.A. Holmans, S. Seshadri, J. Williams, P. Amouyel, G.D. Schellenberg, J.C. Lambert, M.A. Pericak-Vance, Genetic meta-analysis of 344

- diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid
 processing. Nat Genet 2019;51:414-430.
- 347 [7] V.B. Sheppard, L.S. Cox, M.J. Kanamori, J. Canar, Y. Rodriguez, M. Goodman, J. Pomeroy, J.
- 348 Mandelblatt, E.E. Huerta, Latin American Cancer Research Coalition, Brief report: if you build it, they will some methods for recerciting Latings into some research L Can Latern Med 2005;20:444, 447
- will come: methods for recruiting Latinos into cancer research. J Gen Intern Med 2005;20:444-447.
- 350 [8] J.L. Calderon, R.S. Baker, H. Fabrega, J.G. Conde, R.D. Hays, E. Fleming, K. Norris, An ethno-
- 351 medical perspective on research participation: a qualitative pilot study. MedGenMed 2006;8:23.
- [9] V.L. Shavers, C.F. Lynch, L.F. Burmeister, Racial differences in factors that influence the willingness
 to participate in medical research studies. Ann Epidemiol 2002;12:248-256.
- [10] A.G. Ramirez, A.R. Miller, K. Gallion, S. San Miguel de Majors, P. Chalela, S. Garcia Aramburo,
 Testing three different cancer genetics registry recruitment methods with Hispanic cancer patients and
- their family members previously registered in local cancer registries in Texas. Community Genet
- 357 2008;11:215-223.
- [11] D.J. Bowen, V.B. Penchaszadeh, Special issue: enhancing minority recruitment into genetics
 research. Community Genet 2008;11:189-190.
- [12] J. Jacobellis, G. Cutter, Mammography screening and differences in stage of disease by
 race/ethnicity. Am J Public Health 2002;92:1144-1150.
- 362 [13] L. Rahib, M.R. Wehner, L.M. Matrisian, K.T. Nead, Estimated Projection of US Cancer Incidence
- and Death to 2040. JAMA Netw Open 2021;4:e214708.
- 364 [14] J.W. Eley, H.A. Hill, V.W. Chen, D.F. Austin, M.N. Wesley, H.B. Muss, R.S. Greenberg, R.J.
- 365 Coates, P. Correa, C.K. Redmond, Racial differences in survival from breast cancer. Results of the
- 366 National Cancer Institute Black/White Cancer Survival Study. Jama 1994;272:947-954.
- 367 [15] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
- 368 [16] E.D. Paskett, C. Tatum, J. Rushing, R. Michielutte, R. Bell, K.L. Foley, M. Bittoni, S. Dickinson,
- Racial differences in knowledge, attitudes, and cancer screening practices among a triracial rural
 population. Cancer 2004;101:2650-2659.
- 371 [17] J.C. Lennon, S.L. Aita, V.A.D. Bene, T. Rhoads, Z.J. Resch, J.M. Eloi, K.A. Walker, Black and
- White individuals differ in dementia prevalence, risk factors, and symptomatic presentation. Alzheimers
 Dement 2022;18:1461-1471.
- [18] M.X. Tang, G. Maestre, W.Y. Tsai, X.H. Liu, L. Feng, W.Y. Chung, M. Chun, P. Schofield, Y.
- 375 Stern, B. Tycko, R. Mayeux, Relative risk of Alzheimer disease and age-at-onset distributions, based on
- 376 APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J
- 377 Hum Genet 1996;58:574-584.
- 378 [19] M.X. Tang, P. Cross, H. Andrews, D.M. Jacobs, S. Small, K. Bell, C. Merchant, R. Lantigua, R.
- 379 Costa, Y. Stern, R. Mayeux, Incidence of AD in African-Americans, Caribbean Hispanics, and
- 380 Caucasians in northern Manhattan. Neurology 2001;56:49-56.

- 381 [20] B.N. Vardarajan, K.M. Faber, T.D. Bird, D.A. Bennett, R. Rosenberg, B.F. Boeve, N.R. Graff-
- 382 Radford, A.M. Goate, M. Farlow, R.A. Sweet, R. Lantigua, M.Z. Medrano, R. Ottman, D.J. Schaid, T.M.
- 383Foroud, R. Mayeux, NIA-LOAD/NCRAD Family Study Group, Age-specific incidence rates for
- dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on
- 385 Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer
- 386 Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA).
- **387** JAMA Neurol 2014;71:315-323.
- 388 [21] G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr, C.H. Kawas, W.E. Klunk,
- W.J. Koroshetz, J.J. Manly, R. Mayeux, R.C. Mohs, J.C. Morris, M.N. Rossor, P. Scheltens, M.C.
- 390 Carrillo, B. Thies, S. Weintraub, C.H. Phelps, The diagnosis of dementia due to Alzheimer's disease:
- recommendations from the National Institute on Aging-Alzheimer's Association workgroups on
- diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
- 393 [22] S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C.R. Jack, W. Jagust, J.Q. Trojanowski, A.W.
- 394 Toga, L. Beckett, Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease
- Neuroimaging Initiative (ADNI). Alzheimers Dement 2005;1:55-66.
- 396 [23] I.S. van Maurik, S.J. Vos, I. Bos, F.H. Bouwman, C.E. Teunissen, P. Scheltens, F. Barkhof, L.
- 397 Frolich, J. Kornhuber, J. Wiltfang, W. Maier, O. Peters, E. Ruther, F. Nobili, G.B. Frisoni, L. Spiru, Y.
- 398 Freund-Levi, A.K. Wallin, H. Hampel, H. Soininen, M. Tsolaki, F. Verhey, I. Kloszewska, P. Mecocci,
- B. Vellas, S. Lovestone, S. Galluzzi, S. Herukka, I. Santana, I. Baldeiras, A. de Mendonca, D. Silva, G.
 Chetelat, S. Egret, S. Palmqvist, O. Hansson, P.J. Visser, J. Berkhof, W.M. van der Flier, Alzheimer's
- 400 Disease Neuroimaging Initiative, Biomarker-based prognosis for people with mild cognitive impairment
- 402 (ABIDE): a modelling study. Lancet Neurol 2019;18:1034-1044.
- 403 [24] S.E. O'Bryant, M.M. Mielke, R.A. Rissman, S. Lista, H. Vanderstichele, H. Zetterberg, P. Lewczuk,
- 404 H. Posner, J. Hall, L. Johnson, Y. Fong, J. Luthman, A. Jeromin, R. Batrla-Utermann, A. Villarreal, G.
- 405 Britton, P.J. Snyder, K. Henriksen, P. Grammas, V. Gupta, R. Martins, H. Hampel, Biofluid Based
- 406 Biomarker Professional Interest Area, Blood-based biomarkers in Alzheimer disease: Current state of the
- 407 science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement
- 408 2017;13:45-58.
- 409 [25] S.E. Schindler, J.G. Bollinger, V. Ovod, K.G. Mawuenyega, Y. Li, B.A. Gordon, D.M. Holtzman,
- 410 J.C. Morris, T.L.S. Benzinger, C. Xiong, A.M. Fagan, R.J. Bateman, High-precision plasma beta-amyloid
- 411 42/40 predicts current and future brain amyloidosis. Neurology 2019;93:e1647-e1659.
- 412 [26] T.K. Karikari, T.A. Pascoal, N.J. Ashton, S. Janelidze, A.L. Benedet, J.L. Rodriguez, M. Chamoun,
- 413 M. Savard, M.S. Kang, J. Therriault, M. Scholl, G. Massarweh, J.P. Soucy, K. Hoglund, G. Brinkmalm,
- N. Mattsson, S. Palmqvist, S. Gauthier, E. Stomrud, H. Zetterberg, O. Hansson, P. Rosa-Neto, K.
- 415 Blennow, Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic
- 416 performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol
- 417 2020;19:422-433.
- 418 [27] S. Janelidze, N. Mattsson, S. Palmqvist, R. Smith, T.G. Beach, G.E. Serrano, X. Chai, N.K. Proctor,
- 419 U. Eichenlaub, H. Zetterberg, K. Blennow, E.M. Reiman, E. Stomrud, J.L. Dage, O. Hansson, Plasma P-
- 420 tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology
- 421 and longitudinal progression to Alzheimer's dementia. Nat Med 2020;26:379-386.

- 422 [28] A.G. Ramirez, A.R. Miller, K. Gallion, S. San Miguel de Majors, P. Chalela, S. Garcia Aramburo,
- 423 Testing three different cancer genetics registry recruitment methods with Hispanic cancer patients and
- their family members previously registered in local cancer registries in Texas. Community Genet
- **425** 2008;11:215-223.
- [29] G. Sirugo, S.M. Williams, S.A. Tishkoff, The Missing Diversity in Human Genetic Studies. Cell
 2019;177:1080.
- 428 [30] J.C. Morris, S.E. Schindler, L.M. McCue, K.L. Moulder, T.L.S. Benzinger, C. Cruchaga, A.M.
- 429 Fagan, E. Grant, B.A. Gordon, D.M. Holtzman, C. Xiong, Assessment of Racial Disparities in 420 Biomedians for Alphaimer Disease, JAMA Neural 2010;76:264, 272
- 430 Biomarkers for Alzheimer Disease. JAMA Neurol 2019;76:264-273.
- 431 [31] C.E. Gleason, M. Zuelsdorff, D.C. Gooding, A.J.H. Kind, A.L. Johnson, T.T. James, N.H. Lambrou,
- 432 M.F. Wyman, F.B. Ketchum, A. Gee, S.C. Johnson, B.B. Bendlin, H. Zetterberg, Alzheimer's disease
- biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.
- 434 Alzheimers Dement 2022;18:1545-1564.
- [32] K. Armstrong, E. Micco, A. Carney, J. Stopfer, M. Putt, Racial differences in the use of BRCA1/2
 testing among women with a family history of breast or ovarian cancer. Jama 2005;293:1729-1736.
- [33] L. Kessler, S. Domchek, J. Stopfer, C.H. Halbert, BRCA1 and BRCA2 risk perceptions among
 African American women at increased risk for hereditary breast-ovarian cancer. Community Genet
 2008;11:193-200.
- [34] C. Ricker, V. Lagos, N. Feldman, S. Hiyama, S. Fuentes, V. Kumar, K. Gonzalez, M. Palomares, K.
 Blazer, K. Lowstuter, D. MacDonald, J. Weitzel, If we build it ... will they come?--establishing a cancer
 genetics services clinic for an underserved predominantly Latina cohort. Journal of Genetic Counseling
- **443** 2006;15:505-514.
- 444 [35] L. Scheuer, N. Kauff, M. Robson, B. Kelly, R. Barakat, J. Satagopan, N. Ellis, M. Hensley, J. Boyd,
- P. Borgen, L. Norton, K. Offit, Outcome of preventive surgery and screening for breast and ovarian
- 446 cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-1268.
- 447 [36] C. Lerman, C. Hughes, J.L. Benkendorf, B. Biesecker, J. Kerner, J. Willison, N. Eads, D. Hadley, J.
- 448 Lynch, Racial differences in testing motivation and psychological distress following pretest education for
- 449 BRCA1 gene testing. Cancer Epidemiology, Biomarkers & Prevention 1999;8:361-367.
- 450 [37] K. Armstrong, B. Weber, J. Stopfer, K. Calzone, M. Putt, J. Coyne, J.S. Schwartz, Early use of
- 451 clinical BRCA1/2 testing: associations with race and breast cancer risk. American Journal of Medical
 452 Genetics.Part A 2003;117A:154-160.
- 453 [38] K. Deniz, C.C.G. Ho, K.G. Malphrus, J.S. Reddy, T. Nguyen, T.P. Carnwath, J.E. Crook, J.A. Lucas,
- N.R. Graff-Radford, M.M. Carrasquillo, N. Ertekin-Taner, Plasma Biomarkers of Alzheimer's Disease in
 African Americans. J Alzheimers Dis 2021;79:323-334.
- 456 [39] A.M. Brickman, J.J. Manly, L.S. Honig, D. Sanchez, D. Reyes-Dumeyer, R.A. Lantigua, P.J. Lao, Y.
- 457 Stern, J.P. Vonsattel, A.F. Teich, D.C. Airey, N.K. Proctor, J.L. Dage, R. Mayeux, Plasma p-tau181, p-
- tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
- 459 Alzheimers Dement 2021.

- 460 [40] Y. Gu, L.S. Honig, M.S. Kang, A. Bahl, D. Sanchez, D. Reyes-Dumeyer, J.J. Manly, J.L. Dage, R.A.
- Lantigua, A.M. Brickman, B.N. Vardarajan, R. Mayeux, Risk of Alzheimer's disease is associated with
- 462 longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights-Hamilton Heights-
- 463 Inwood Columbia Aging Project (WHICAP) cohort. Alzheimers Dement 2024.
- 464 [41] M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, A. Gamst, D.M.
- 465 Holtzman, W.J. Jagust, R.C. Petersen, P.J. Snyder, M.C. Carrillo, B. Thies, C.H. Phelps, The diagnosis of
- 466 mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on
- 467 Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers
- 468 Dement 2011;7:270-279.
- 469 [42] B. Croisile, S. Auriacombe, F. Etcharry-Bouyx, M. Vercelletto, National Institute on Aging (u.s.),
- 470 Alzheimer Association, The new 2011 recommendations of the National Institute on Aging and the
- 471 Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive
- 472 impairment, and dementia. Rev Neurol (Paris) 2012;168:471-482.
- 473 [43] M.P. Conomos, S.M. Gogarten, L. Brown, H. Chen, K. Rice, T. Sofer, T. Thornton, C. Yu,
- 474 GENESIS: GENetic EStimation and Inference in Structured samples (GENESIS): Statistical methods for
- analyzing genetic data from samples with population structure and/or relatedness. 2019;R package
- 476 version 2.14.3.
- [44] A. Manichaikul, J.C. Mychaleckyj, S.S. Rich, K. Daly, M. Sale, W.M. Chen, Robust relationship
 inference in genome-wide association studies. Bioinformatics 2010;26:2867-2873.
- [45] L.L. Cavalli-Sforza, The Human Genome Diversity Project: past, present and future. Nat Rev Genet
 2005;6:333-340.
- [46] D.H. Alexander, J. Novembre, K. Lange, Fast model-based estimation of ancestry in unrelated
 individuals. Genome Res 2009;19:1655-1664.
- 483 [47] D.H. Wilson, D.M. Rissin, C.W. Kan, D.R. Fournier, T. Piech, T.G. Campbell, R.E. Meyer, M.W.
- Fishburn, C. Cabrera, P.P. Patel, E. Frew, Y. Chen, L. Chang, E.P. Ferrell, V. von Einem, W. McGuigan,
 M. Reinhardt, H. Sayer, C. Vielsack, D.C. Duffy, The Simoa HD-1 Analyzer: A Novel Fully Automated
- 486 Digital Immunoassay Analyzer with Single-Molecule Sensitivity and Multiplexing. J Lab Autom
- 487 2016;21:533-547.
- [48] A. Kuznetsova, P.B. Brockhoff, R.H.B. Christensen, ImerTest Package: Tests in Linear Mixed
 Effects Models. Journal of Statistical Software 2017;82:1–26.
- [49] T. Hothorn, F. Bretz, P. Westfall, Simultaneous inference in general parametric models. Biom J
 2008;50:346-363.
- 492 [50] R.V. Lenth, Least-Squares Means: The R Package Ismeans. Journal of Statistical Software493 2016;69:1–33.
- 494 [51] X. Robin, N. Turck, A. Hainard, N. Tiberti, F. Lisacek, J. Sanchez, M. Müller, pROC: an open495 source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
- 496 [52] A. Kassambara, Ggpubr: 'Ggplot2' Based Publication Ready Plots; 2020.

- 497 [53] S. Palmqvist, S. Janelidze, Y.T. Quiroz, H. Zetterberg, F. Lopera, E. Stomrud, Y. Su, Y. Chen, G.E.
 498 Serrano, A. Leuzy, N. Mattsson-Carlgren, O. Strandberg, R. Smith, A. Villegas, D. Sepulveda-Falla, X.
 499 Chai, N.K. Proctor, T.G. Beach, K. Blennow, J.L. Dage, E.M. Reiman, O. Hansson, Discriminative
 500 Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. Jama
 501 2020;324:772-781.
- [54] S. Janelidze, D. Bali, N.J. Ashton, N.R. Barthelemy, J. Vanbrabant, E. Stoops, E. Vanmechelen, Y.
 He, A.O. Dolado, G. Triana-Baltzer, M.J. Pontecorvo, H. Zetterberg, H. Kolb, M. Vandijck, K. Blennow,
 R.J. Bateman, O. Hansson, Head-to-head comparison of 10 plasma phospho-tau assays in prodromal
 Alzheimer's disease. Brain 2023;146:1592-1601.
- 506 [55] J.R. Hall, M. Petersen, L. Johnson, S.E. O'Bryant, Characterizing Plasma Biomarkers of Alzheimer's
 507 in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort. Front Neurol
 508 2022;13:871947.
- 509

510 Consent Statement

- 511 All participants, or their proxy, provided written informed consent as part of the study protocols approved
- 512 by the site-specific Institutional Review Boards.

513 Acknowledgements

- 514 We acknowledge the participation of the individuals included in this study. Biomarker data was generated
- 515 in collaboration with the Center for Genome Technology (CGT) from the John P. Hussman Institute for
- 516 Human Genomics (HIHG).
- 517 Funding
- 518 This work was supported by the National Institutes of Health National Institute on Aging (grant numbers

519 AG070935 to A.J.G and AG072547, AG052410, AG070864, and AG074865 to M.A.P.V.)

520 Conflict of Interest

- 521 The authors declare no conflicts of interest.
- 522 Key Words
- 523 Alzheimer's disease; diverse ancestry; plasma biomarkers; tau; amyloid

525 Figure Legends

526	Figure 1. Global genomic ancestry analysis. A) Principal component analyses. Estimation of relationship
527	to ancestral reference groups from Human Genome Diversity Project (HGDP): Maroon = African, Green
528	= Amerindian, Yellow = East Asian, Blue = European, or each sample cohort: Light Green = Cuban
529	American, Violet = Peruvian, Red = Puerto Rican, Aqua = African American. B) Ancestral admixture
530	estimations. Each column on the X-axis represents one participant. Colors in each vertical line represent
531	the proportion of ancestral admixture. Red = African, Blue = European, Green = Amerindian, Yellow =
532	East Asian.
533	Figure 2. AD biomarker levels across ancestral groups African Americans, Peruvians, and Caribbean
534	Hispanics. A) pTau-181 in cognitively unimpaired. B) pTau-181 in AD. C) Aβ42/Aβ40 in cognitively
535	unimpaired. D) Aβ42/Aβ40 in AD. **** p<0.0001, ***p<0.001, **p<0.01, *p<0.05, ns = not significant
536	Figure 3. Plasma pTau-181 comparison analysis. Comparisons of the pTau-181 concentration in clinical
537	diagnosis statuses of Alzheimer Disease (AD), mild cognitively impaired (MCI), or cognitively
538	unimpaired (CU) in: A) The overall combined cohort, B) African Americans, C) Peruvians, and D)
539	Caribbean Hispanics. Each point represents one individual's pTau-181 measurement. Concentrations are
540	shown as median ± interquartile range, **** p<0.0001, ***p<0.001, **p<0.01, *p<0.05, ns = not
541	significant
542	Figure 4. Plasma Aβ42/Aβ40 ratio comparison analysis. Comparisons of the Aβ42/Aβ40 ratio in clinical
543	diagnosis statuses of Alzheimer Disease (AD), mild cognitively impaired (MCI), or cognitively
544	unimpaired (CU) in: A) The overall combined cohort, B) African Americans, C) Peruvians, and D)
545	Caribbean Hispanics. Each point represents one individual's $A\beta 42/A\beta 40$ ratio. Ratios are shown as
546	median \pm interquartile range, *p<0.05, ns = not significant
547	Figure 5. pTau-181 and Aβ42/Aβ40 ratio comparisons in African American plasma and serum analysis.
548	Comparisons of pTau-181 concentrations between serum and plasma in A) cognitively unimpaired (CU)
549	and B) Alzheimer Disease (AD). A β 42/A β 40 ratio between serum and plasma in C) cognitively

- unimpaired (CU) and **D**) Alzheimer Disease (AD). Each point represents one individual's measurement.
- 551 Concentrations are shown as median ± interquartile range. **** p<0.0001, **p<0.01, *p<0.05
- **Figure 6.** Serum pTau-181 and Aβ42/Aβ40 ratio comparison analysis. Comparisons of the A) pTau 181
- 553 concentration and **B**) Aβ42/Aβ40 ratio in clinical diagnosis statuses of Alzheimer Disease (AD), mild
- cognitively impaired (MCI), or cognitively unimpaired (CU) in a subset of African American individuals
- 555 for which plasma was not available. Each point represents one individual's measurement. Concentrations
- are shown as median \pm interquartile range. ****p < 0.0001, ns not significant.
- 557 Figure 7. Receiver operating characteristic (ROC) curves of plasma and serum biomarkers for the
- classification of Alzheimer disease status in: A) The overall combined cohort, B) Caribbean Hispanics, C)
- 559 Peruvians, D) African Americans plasma, E) African Americans serum. Red lines represent pTau-181
- alone, green lines $A\beta 42/A\beta 40$ ratio alone, and blue lines the combination of pTau-181 and $A\beta 42/A\beta 40$

561 ratio.



East Asian

A. ptau-181 in CU

B. ptau-181 in AD

C. Aβ42/Aβ40 ratio in CU

D. Aβ42/Aβ40 ratio in AD





B. African American



A. All Samples

B. African American





A. Serum pTau181 level

B. Serum Aβ42/Aβ40 ratio





log10 pTau181 — log10 ratio of Aβ42 to Aβ40 — log10 pTau181 and log10 ratio of Aβ42 to Aβ40

A. All Samples

B. Caribbean Hispanic

C. Peruvian